Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101937 | 0.85 | ESR2 (0.53) | ESR2ESR1MAOAKDM4EALDH1A1 | |
| SCHEMBL29923014 | 0.85 | ESR2 (0.53) | ESR2ESR1MAOAKDM4EALDH1A1 | |
| SCHEMBL7228032 | 0.84 | ESR2 (1.00) | ESR2ESR1MAOAKDM4EALDH1A1 | |
| SCHEMBL7227909 | 0.80 | ESR2 (0.67) | ESR2ESR1MAOAKDM4EALDH1A1 | |
| Xanthone SCHEMBL9175420 | 0.78 | MAOA (0.72) | MAOAKDM4EALDH1A1GLACYP3A4 | |
| SCHEMBL17689908 | 0.77 | ESR2 (0.49) | ESR2ESR1MAOAKDM4EALDH1A1 | |
| SCHEMBL7228385 | 0.75 | ESR2 (1.00) | ESR2ESR1MAOACYP3A4MAPT | |
| SCHEMBL19419237 | 0.74 | ESR2 (0.46) | ESR2ESR1MAOAKDM4EALDH1A1 | |
| SCHEMBL24071854 | 0.73 | ESR2 (0.47) | ESR2ESR1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL22012012 | 0.72 | ESR2 (0.43) | ESR2ESR1MAOAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104725399-B | Method for using ionic liquid to promote intramolecular cross dehydrogenation coupling so as to synthesize benzothieno[3,2-b]chromone compounds | 新疆大学 | 2017-05-24 | — | — | CN | disclosed |
| CN-104725399-B | Method for using ionic liquid to promote intramolecular cross dehydrogenation coupling so as to synthesize benzothieno[3,2-b]chromone compounds | 新疆大学 | 2017-05-24 | — | — | CN | disclosed |
| CN-104725399-A | Method for using ionic liquid to promote intramolecular cross dehydrogenation coupling so as to synthesize benzothieno[3,2-b]chromone compounds | UNIV XINJIANG | 2015-06-24 | — | — | CN | disclosed |
| CN-104725399-A | Method for using ionic liquid to promote intramolecular cross dehydrogenation coupling so as to synthesize benzothieno[3,2-b]chromone compounds | UNIV XINJIANG | 2015-06-24 | — | — | CN | disclosed |
| US-6559177-B2 | For therapy or inhibiting osteoporosis or inhibiting bone demineralization, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis in mammal | WYETH | 2003-05-06 | — | — | US | disclosed |
| US-6559177-B2 | For therapy or inhibiting osteoporosis or inhibiting bone demineralization, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis in mammal | WYETH | 2003-05-06 | — | — | US | disclosed |
| US-20020183310-A1 | 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents | WYETH | 2002-12-05 | — | — | US | disclosed |
| US-20020183310-A1 | 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents | WYETH | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183310-A1 | 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents | ESR1, GPER1, ESR2 | ESR2 3/4885ESR1 1/4885MAOA 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.